Prospects for new and emerging therapeutics in severe asthma: the role of biologics.

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.

Development of New Therapies for Severe Asthma

Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.

A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.

Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Effect of asthma therapies on the natural course of asthma.

Prospects for new and emerging therapeutics in severe asthma: the role of biologics.

Toward Better Management for Asthma: From Smart Inhalers to Injections to Wearables, Researchers Are Finding New Ways to Improve Asthma Treatment

Performance of the Alere i RSV assay for point-of-care detection of respiratory syncytial virus in children

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.

Development of New Therapies for Severe Asthma

Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.

A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.

Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Effect of asthma therapies on the natural course of asthma.

Prospects for new and emerging therapeutics in severe asthma: the role of biologics.

Toward Better Management for Asthma: From Smart Inhalers to Injections to Wearables, Researchers Are Finding New Ways to Improve Asthma Treatment

Performance of the Alere i RSV assay for point-of-care detection of respiratory syncytial virus in children

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.

Development of New Therapies for Severe Asthma

Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.

A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.

Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Effect of asthma therapies on the natural course of asthma.